Sweden· SE-20140903000081
Zerbaxa 1 g/0,5 g Pulver till koncentrat till infusionsvätska, lösning
A medicinal product containing tazobactam + ceftolozane, registered in Sweden by Merck Sharp & Dohme BV.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Tazobactam + Ceftolozane
- Manufacturer
- Merck Sharp & Dohme BV
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20140903000081
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tazobactam + ceftolozane in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaZERBAXAMERCK CANADA INC
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d995864d-01bb-41f4-894e-24d477d7ad63 GET /v1/drugs/d995864d-01bb-41f4-894e-24d477d7ad63?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"Dispensbeslut",
"EMA",
"EPAR"
],
"se_npl_id": "20140903000081",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20140903000081",
"product_doc_link": "https://docetp.mpa.se/LMF/Zerbaxa%2C%20sammanfattning%20av%20beslut%2C%20giltigt%20fr.o.m.%202026-09-29%20t.o.m.%202035-01-01%20%28f%C3%B6rp.%20med%20engelsk%20och%20portugisisk%20m%C3%A4rkning%20och%20engelsk%20och%20portugisisk%20bipacksedel%29_09001bee852fcaae.pdf"
}See everything about tazobactam + ceftolozane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.